Estradiol/norethisterone

{{Short description|Combination drug}}

{{Distinguish|Ethinylestradiol/norethisterone|Estradiol/norethisterone acetate}}

{{Drugbox

| image = Estradiol.svg

| width = 225px

| caption = Estradiol

| image2 = Norethisterone.svg

| width2 = 225px

| caption2 = Norethisterone

| type = combo

| drug_name = Estradiol/norethisterone

| component1 = Estradiol

| class1 = Estrogen

| component2 = Norethisterone

| class2 = Progestogen; Progestin

| tradename =

| Drugs.com =

| MedlinePlus =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US = Rx-only

| routes_of_administration = By mouth

| class = Estrogen; Progestin; Progestogen

| CAS_number = 62057-27-6

| ATC_prefix =

| ATC_suffix =

| PubChem =

| DrugBank =

| synonyms = E2/NET; Netagen; Netagen 403

}}

Estradiol/norethisterone (E2/NET), tentative brand name Netagen or Netagen 403, was a combination of estradiol (E2), an estrogen, and norethisterone (NET), a progestin, which was studied as a birth control pill to prevent pregnancy in women.{{cite journal | vauthors = Fruzzetti F, Bitzer J | title = Review of clinical experience with estradiol in combined oral contraceptives | journal = Contraception | volume = 81 | issue = 1 | pages = 8–15 | date = January 2010 | pmid = 20004267 | doi = 10.1016/j.contraception.2009.08.010 }}{{cite journal | vauthors = Astedt B, Svanberg L, Jeppsson S, Liedholm P, Rannevik G | title = The natural oestrogenic hormone oestradiol as a new component of combined oral contraceptives | journal = Br Med J | volume = 1 | issue = 6056 | pages = 269 | date = January 1977 | pmid = 319864 | pmc = 1604185 | doi = 10.1136/bmj.1.6056.269 }}{{cite journal | vauthors = Astedt B, Jeppsson S, Liedholm P, Rannevik G, Svanberg L | title = Clinical trial of a new oral contraceptive pill containing the natural oestrogen 17 beta-oestradiol | journal = Br J Obstet Gynaecol | volume = 86 | issue = 9 | pages = 732–6 | date = September 1979 | pmid = 387069 | doi = 10.1111/j.1471-0528.1979.tb11276.x | s2cid = 72299078 }}{{cite journal | vauthors = Samsioe G, Skryten A, Silfverstolpe G | title = Oral contraception with a nonalkylated estrogen component. Effects on lipid metabolism | journal = Gynecol. Obstet. Invest. | volume = 15 | issue = 5 | pages = 275–82 | date = 1983 | pmid = 6852647 | doi = 10.1159/000299421 }}{{cite journal | vauthors = Skouby SO, Jensen BM, Kühl C, Mølsted-Pedersen L, Svenstrup B, Nielsen J | title = Hormonal contraception in diabetic women: acceptability and influence on diabetes control and ovarian function of a nonalkylated estrogen/progestogen compound | journal = Contraception | volume = 32 | issue = 1 | pages = 23–31 | date = July 1985 | pmid = 4053603 | doi = 10.1016/0010-7824(85)90113-1 }} It was taken by mouth and contained 4 mg micronized E2 and 3 mg NET per tablet. The medication was developed by Novo Pharmaceuticals in Denmark and was never marketed.

Two related formulations were Netagen 423 (4 mg estradiol, 2 mg estriol, 3 mg norethisterone) and Netasyn (50 μg ethinylestradiol, 3 mg norethisterone), were also studied but never marketed.